Identification of Differential Tumor Subtypes of T1 Bladder Cancer

医学 膀胱癌 膀胱切除术 原位癌 淋巴血管侵犯 肿瘤科 内科学 癌症 癌症研究 转移
作者
A. Gordon Robertson,Clarice S. Groeneveld,Brian Jordan,Xiquo Lin,Kimberly A. McLaughlin,Arighno Das,Leigh Ann Fall,Damiano Fantini,Timothy Taxter,Lauren S. Mogil,Sia V. Lindskrog,Lars Dyrskjøt,David James McConkey,Robert Scott Svatek,Aurélien de Reyniès,Mauro A. A. Castro,Joshua J. Meeks
出处
期刊:European Urology [Elsevier BV]
卷期号:78 (4): 533-537 被引量:155
标识
DOI:10.1016/j.eururo.2020.06.048
摘要

Stage T1 bladder cancers have the highest progression and recurrence rates of all non–muscle-invasive bladder cancers (NMIBCs). Most T1 cancers are treated with bacillus Calmette-Guérin (BCG), but many will progress or recur, and some T1 patients will die from bladder cancer. Particularly aggressive tumors could be treated with early cystectomy. To better understand the molecular heterogeneity of T1 cancers, we performed transcriptome profiling and unsupervised clustering, and identified five consensus subtypes of T1 tumors treated with repeat transurethral resection (reTUR) and induction and maintenance BCG. The T1-LumGU subtype was associated with carcinoma in situ (CIS; six/13, 46% of all CIS), had high E2F1 and EZH2 expression, and was enriched in E2F target and G2M checkpoint hallmarks. The T1-Inflam subtype was inflamed and infiltrated with immune cells. While most T1 tumors were classified as luminal papillary, the T1-TLum subtype had the highest median luminal papillary score and FGFR3 expression, no recurrence events, and the fewest copy number gains. T1-Myc and T1-Early subtypes had the most recurrences (14/30 within 24 mo), the highest median MYC expression, and, when combined, had significantly worse recurrence-free survival than the other three subtypes. T1-Early had five (38%) recurrences within the first 6 mo of BCG, and repressed IFN-α and IFN-γ hallmarks and inflammation. We developed a single-patient T1 classifier and validated our subtype biology in a second cohort of T1 tumors. Future research will be necessary to validate the proposed T1 subtypes and to determine if therapies can be individualized for each subtype. We identified and characterized expression subtypes of high-grade stage T1 bladder cancer that are biologically heterogeneous and have variable responses to bacillus Calmette-Guérin treatment. We validated the subtypes and describe a single-patient classifier.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ZL完成签到,获得积分10
刚刚
刚刚
王佳瑶完成签到,获得积分10
刚刚
1秒前
1秒前
2秒前
嘛丝丝完成签到,获得积分10
2秒前
3秒前
富贵儿完成签到,获得积分10
3秒前
3秒前
科研通AI6.2的应助被孙某人采纳,获得30
3秒前
姜丝罐罐n完成签到 ,获得积分10
4秒前
5秒前
爱听歌的听荷完成签到,获得积分10
5秒前
GUESSSS发布了新的文献求助10
6秒前
7秒前
ainiyiwannian完成签到,获得积分10
7秒前
Mars完成签到,获得积分10
7秒前
8秒前
shan发布了新的文献求助10
9秒前
悦耳从波的应助被wang采纳,获得10
9秒前
小黑皮完成签到,获得积分10
10秒前
Beni完成签到,获得积分10
11秒前
边伯贤完成签到 ,获得积分10
11秒前
无花果的应助被谨慎的秋烟采纳,获得10
12秒前
眯眯眼的谷冬完成签到 ,获得积分10
12秒前
agog完成签到,获得积分10
12秒前
HYZJIA1完成签到 ,获得积分10
13秒前
砚行书完成签到,获得积分10
14秒前
醉熏的灵安完成签到 ,获得积分10
14秒前
14秒前
挚友发布了新的文献求助20
14秒前
Ava的应助被peace采纳,获得10
15秒前
慕容平安发布了新的文献求助10
16秒前
Sirius完成签到,获得积分10
17秒前
灰太狼完成签到,获得积分10
17秒前
珍波椰冰冰完成签到,获得积分10
17秒前
糊涂的飞珍完成签到,获得积分10
17秒前
张新宁完成签到,获得积分10
18秒前
饭团发布了新的文献求助10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211